The optimal treatment sequences to maximize the clinical benefit for patients with metastatic castration-resistant prostate cancer (mCRPC) have not been defined. A new prospective, randomized trial on optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in mCRPC investigated whether one regimen resulted in superior outcomes.

中文翻译：

---

前列腺癌中抗雄激素的测序顺序重要吗？

尚未确定使转移性去势抵抗性前列腺癌（mCRPC）患者获得最大临床收益的最佳治疗顺序。一项关于mCRPC中enzalutamide和醋酸阿比特龙酯加泼尼松的最佳测序的新的前瞻性随机试验研究了一种方案是否能带来更好的结果。